Pfizer lifts 2026 outlook as Eliquis demand stays strong
Nov 2 (Reuters) - Pfizer boosted its full-year profit and sales projections on Tuesday, leaning on robust demand for Eliquis, its blood thinner.
The U.S. drugmaker now projects annual revenue of $62 billion to $64.0 billion, compared with its earlier range of $60.5 billion to $62.5 billion. It expects adjusted earnings per share of $2.95 to $3.05 for the year, versus a prior forecast of $2.80 to $3.00.
Analysts on average expected annual per-share profit of $2.96 and 2026 revenue of $62.17 billion.